These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1309 related articles for article (PubMed ID: 23352196)

  • 1. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
    Heier JS; Brown DM; Chong V; Korobelnik JF; Kaiser PK; Nguyen QD; Kirchhof B; Ho A; Ogura Y; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Groetzbach G; Sommerauer B; Sandbrink R; Simader C; Schmidt-Erfurth U;
    Ophthalmology; 2012 Dec; 119(12):2537-48. PubMed ID: 23084240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
    Boyer DS; Heier JS; Brown DM; Francom SF; Ianchulev T; Rubio RG
    Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.
    Jackson TL; Chakravarthy U; Kaiser PK; Slakter JS; Jan E; Bandello F; O'Shaughnessy D; Gertner ME; Danielson L; Moshfeghi DM;
    Ophthalmology; 2013 Sep; 120(9):1893-900. PubMed ID: 23490327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).
    Nguyen QD; Schachar RA; Nduaka CI; Sperling M; Klamerus KJ; Chi-Burris K; Yan E; Paggiarino DA; Rosenblatt I; Aitchison R; Erlich SS;
    Ophthalmology; 2012 Sep; 119(9):1867-73. PubMed ID: 22683252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration.
    Stoller GL; Kokame GT; Dreyer RF; Shapiro H; Tuomi LL
    JAMA Ophthalmol; 2016 May; 134(5):545-553. PubMed ID: 27010625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
    Larsen M; Schmidt-Erfurth U; Lanzetta P; Wolf S; Simader C; Tokaji E; Pilz S; Weisberger A;
    Ophthalmology; 2012 May; 119(5):992-1000. PubMed ID: 22424834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.
    Campochiaro PA; Brown DM; Awh CC; Lee SY; Gray S; Saroj N; Murahashi WY; Rubio RG
    Ophthalmology; 2011 Oct; 118(10):2041-9. PubMed ID: 21715011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of the comparisons of age-related macular degeneration treatments trials on clinical practice: what have we learned?
    Do DV
    Ophthalmology; 2013 May; 120(5 Suppl):S8-10. PubMed ID: 23642785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
    Kaiser PK; Boyer DS; Cruess AF; Slakter JS; Pilz S; Weisberger A;
    Ophthalmology; 2012 May; 119(5):1001-10. PubMed ID: 22444829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
    Brown DM; Nguyen QD; Marcus DM; Boyer DS; Patel S; Feiner L; Schlottmann PG; Rundle AC; Zhang J; Rubio RG; Adamis AP; Ehrlich JS; Hopkins JJ;
    Ophthalmology; 2013 Oct; 120(10):2013-22. PubMed ID: 23706949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing.
    Heier JS; Boyer D; Nguyen QD; Marcus D; Roth DB; Yancopoulos G; Stahl N; Ingerman A; Vitti R; Berliner AJ; Yang K; Brown DM;
    Ophthalmology; 2011 Jun; 118(6):1098-106. PubMed ID: 21640258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration.
    Csaky KG; Dugel PU; Pierce AJ; Fries MA; Kelly DS; Danis RP; Wurzelmann JI; Xu CF; Hossain M; Trivedi T
    Ophthalmology; 2015 Mar; 122(3):579-88. PubMed ID: 25432081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
    Sarraf D; London NJ; Khurana RN; Dugel PU; Gune S; Hill L; Tuomi L
    Ophthalmology; 2016 Oct; 123(10):2213-24. PubMed ID: 27566855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
    Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
    Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2.
    Abraham P; Yue H; Wilson L
    Am J Ophthalmol; 2010 Sep; 150(3):315-324.e1. PubMed ID: 20598667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
    Brown DM; Campochiaro PA; Singh RP; Li Z; Gray S; Saroj N; Rundle AC; Rubio RG; Murahashi WY;
    Ophthalmology; 2010 Jun; 117(6):1124-1133.e1. PubMed ID: 20381871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.